Official Title
Maintenance Electroconvulsive Therapy (ECT) Versus Aripiprazole on Psychopathology and Cerebral Perfusion in Clozapine-resistant Schizophrenia: a Randomized, Double-blind Controlled Trial
Brief Summary

The pharmacological treatment options in schizophrenia developing resistance to clozapineare limited. Few studies have found ECT as beneficial in TRS, including CRS. However,literature on the role of M-ECT in maintaining the therapeutic gains of acute ECT in CRSis lacking. The objective of the study is to compare the efficacy of M-ECT vsaripiprazole as an add-on to ongoing clozapine on the severity of symptom dimensions,cerebral perfusion, global functioning and cognitions in patients with CRS.

Detailed Description

Not Provided

Not yet recruiting
Clozapine Resistant Schizophrenia

Procedure: maintenance ECT

Frequency of weekly sessions for 1 month, then fortnightly for 5 months

Drug: Aripiprazole tablet

Aripiprazole 10 mg in the morning throughout the study period

Eligibility Criteria

Inclusion Criteria:

1. Patients clinically diagnosed with CRS (currently under clozapine)

2. Patients aged 18-60 years of either sex.

3. LAR giving voluntary written consent for participation in the study

Exclusion Criteria:

1. Patient already on ECT or aripiprazole.

2. History of psychoactive substance abuse or dependence.

3. Co-morbid psychiatric, major medical or neurological disorders.

4. History of organicity or significant head injury.

5. Pacemaker or metal in any body part, excluding the mouth. Pregnant and breastfeeding
females.

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: 60 Years
Locations

Not Provided

Contacts

Biswa Ranjan Mishra, MD
9438884220
psych_biswa@aiimsbhubaneswar.edu.in

Rituparna Maiti, MD, Study Director
AIIMS Bhubaneswar

All India Institute of Medical Sciences, Bhubaneswar
NCT Number
Keywords
Clozapine resistant
schizophrenia
Aripiprazole
m-ECT
MeSH Terms
Schizophrenia
Aripiprazole